Group 1 - Fujilai's stock price increased by 5.11% on January 19, reaching 37.24 CNY per share, with a trading volume of 68.30 million CNY and a turnover rate of 2.10%, resulting in a total market capitalization of 3.414 billion CNY [1] - The stock has risen for three consecutive days, with a cumulative increase of 3.75% during this period [1] - Fujilai Pharmaceutical Co., Ltd. specializes in the research, production, and sales of active pharmaceutical ingredients and health product raw materials, with its main revenue sources being lipoic acid series products (66.02%), carnosine series products (14.86%), etoricoxib (11.88%), phosphatidylcholine series products (5.95%), and others (1.29%) [1] Group 2 - Among Fujilai's top ten circulating shareholders, a fund under Galaxy Fund, Galaxy Kangle Stock A (519673), entered the top ten in the third quarter, holding 178,100 shares, which is 0.2% of the circulating shares [2] - The fund has reportedly earned approximately 322,400 CNY in floating profit today, with a floating profit of 228,000 CNY during the three-day increase [2] - Galaxy Kangle Stock A was established on November 18, 2014, with a current scale of 156 million CNY, achieving a year-to-date return of 21.5% and a one-year return of 45.15% [2]
富士莱股价涨5.11%，银河基金旗下1只基金位居十大流通股东，持有17.81万股浮盈赚取32.24万元